Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine Inc. (CMND) has successfully closed an underwritten public offering of 1,153,847 common shares at a price of US$6.50 each, raising gross proceeds of US$7.5 million. This offering follows a 1-for-30 reverse stock split effective September 30, 2022. Aegis Capital Corp. has a 45-day option to purchase up to 173,077 additional shares, potentially bringing total proceeds to about US$8.6 million. The company focuses on developing novel psychedelic-derived therapeutics for major health issues, supported by a robust intellectual property portfolio.